Combatting Silicosis Fibrosis: Methyl Gallate Suppresses Pathogenic Fibroblasts Through hnRNPA2 / B1 ‐ MDM4 ‐ P53 Network Disruption
The FASEB Journal · 2026
DOI: 10.1096/fj.202502303rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Y Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Fibroblasts, Heterogeneous-Nuclear Ribonucleoprotein Group A-B, Proto-Oncogene Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Scientific Research Projects of Colleges and Universities of Henan Province, Training Program for Young Core Faculty in Undergraduate Universities in Henan Province.
Abstract (Originalsprache)
Silicosis, an occupational pulmonary fibrosis caused by silica dust exposure, lacks effective treatments. This study investigates the therapeutic potential and mechanism of methyl gallate (MG), a natural polyphenol, in silicosis fibrosis. A silica‐induced silicosis mouse model and TGF‐β1‐stimulated human lung fibroblasts were employed. MG administration significantly ameliorated lung fibrosis in mice, reducing collagen deposition, α‐SMA, fibronectin, and TGF‐β1 levels. Transcriptomic analysis revealed that MG inhibited fibroblast activation by suppressing cell cycle progression via CDK6‐mediated G0/G1 arrest. Mechanistically, MG downregulated MDM4 protein levels, disrupted MDM4‐P53 interaction, and activated the P53‐P21 pathway, promoting fibroblast apoptosis and cell cycle arrest. Further, Drug Affinity Responsive Target Stability (DARTS) and Cellular Thermal Shift Assay (CETSA) identified hnRNPA2/B1 as MG's direct target. MG inhibited hnRNPA2/B1‐mediated MDM4 mRNA translation, thereby reducing MDM4 protein synthesis. Overexpression of MDM4 or knockdown of hnRNPA2/B1 reversed MG's anti‐fibrotic effects. These findings highlight MG's novel role in alleviating silicosis fibrosis by targeting the hnRNPA2/B1‐MDM4‐P53 axis, offering a promising therapeutic strategy for silicosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province & Education Ministry of P.R. China, Zhengzhou, Henan, China.
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
- Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
ORCID-Profile: P Zhao
Förderung
- National Natural Science Foundation of China
- Key Scientific Research Projects of Colleges and Universities of Henan Province
- Training Program for Young Core Faculty in Undergraduate Universities in Henan Province
Zitieren
APA
Wei, Y., Wu, Y. J., He, W. R., Zhao, P., Zhang, Q., & Li, J. S. (2026). Combatting Silicosis Fibrosis: Methyl Gallate Suppresses Pathogenic Fibroblasts Through hnRNPA2 / B1 ‐ MDM4 ‐ P53 Network Disruption. The FASEB Journal. https://doi.org/10.1096/fj.202502303rr
Vancouver
Wei Y, Wu YJ, He WR, Zhao P, Zhang Q, Li JS. Combatting Silicosis Fibrosis: Methyl Gallate Suppresses Pathogenic Fibroblasts Through hnRNPA2 / B1 ‐ MDM4 ‐ P53 Network Disruption. The FASEB Journal. 2026. doi:10.1096/fj.202502303rr
BibTeX
@article{Wei2026,
author = {Wei, Y and Wu, Y J and He, W R and Zhao, P and Zhang, Q and Li, J S},
title = {Combatting Silicosis Fibrosis: Methyl Gallate Suppresses Pathogenic Fibroblasts Through hnRNPA2 / B1 ‐ MDM4 ‐ P53 Network Disruption},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202502303rr}
}
EUVIMED